How to buy Genmab A/S stock - 02 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Genmab A/S stock

Own Genmab A/S stock in just a few minutes.

Fact checked

Genmab A/S is a biotechnology business based in the US. Genmab A/S shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Genmab A/S employs 712 staff and has a market cap (total outstanding shares value) of USD$24.4 billion.

How to buy shares in Genmab A/S

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Genmab A/S. Find the stock by name or ticker symbol: GMAB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Genmab A/S reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Genmab A/S, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Genmab A/S. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Genmab A/S share price

Use our graph to track the performance of GMAB stocks over time.

Genmab A/S shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$16.24 - USD$44.83
50-day moving average USD$41.3085
200-day moving average USD$38.2094
Wall St. target priceUSD$42.14
PE ratio 26.5876
Dividend yield N/A (0%)
Earnings per share (TTM) USD$33.1853

Buy Genmab A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genmab A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Genmab A/S under- or over-valued?

Valuing Genmab A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Genmab A/S's P/E ratio

Genmab A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Genmab A/S shares trade at around 27x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Genmab A/S's PEG ratio

Genmab A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4684. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Genmab A/S financials

Gross profit TTM USD$5.4 billion
Return on assets TTM 27.27%
Return on equity TTM 36.46%
Profit margin 51.22%
Book value N/A
Market capitalisation USD$24.4 billion

TTM: trailing 12 months

Shorting Genmab A/S shares

There are currently 428,044 Genmab A/S shares held short by investors – that's known as Genmab A/S's "short interest". This figure is 49.6% down from 848,966 last month.

There are a few different ways that this level of interest in shorting Genmab A/S shares can be evaluated.

Genmab A/S's "short interest ratio" (SIR)

Genmab A/S's "short interest ratio" (SIR) is the quantity of Genmab A/S shares currently shorted divided by the average quantity of Genmab A/S shares traded daily (recently around 586361.64383562). Genmab A/S's SIR currently stands at 0.73. In other words for every 100,000 Genmab A/S shares traded daily on the market, roughly 730 shares are currently held short.

However Genmab A/S's short interest can also be evaluated against the total number of Genmab A/S shares, or, against the total number of tradable Genmab A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genmab A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genmab A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genmab A/S shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genmab A/S.

Find out more about how you can short Genmab A/S stock.

Genmab A/S share dividends

We're not expecting Genmab A/S to pay a dividend over the next 12 months.

Have Genmab A/S's shares ever split?

Genmab A/S's shares were split on a 5:1 basis on 1 May 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab A/S shares which in turn could have impacted Genmab A/S's share price.

Genmab A/S share price volatility

Over the last 12 months, Genmab A/S's shares have ranged in value from as little as $16.24 up to $44.83. A popular way to gauge a stock's volatility is its "beta".

GMAB.US volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab A/S's is 0.5638. This would suggest that Genmab A/S's shares are less volatile than average (for this exchange).

Genmab A/S overview

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site